MeSH term
Frequency | Condition_Probility | Chromosomes, Human, Pair 18/*genetics | 2 | 2.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Humans | 15 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 13 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Adult | 4 | 0.0 |
Aged | 2 | 0.0 |
Female | 7 | 0.0 |
Genotype | 5 | 0.0 |
Male | 6 | 0.0 |
Middle Aged | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Thymidylate Synthase/*genetics/metabolism | 3 | 60.0 |
Animals | 3 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Thymidylate Synthase/*genetics | 3 | 13.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Forecasting | 2 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Predictive Value of Tests | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Research Support, U.S. Gov't, P.H.S. | 3 | 0.0 |
Thymidylate Synthase/genetics | 2 | 15.0 |
Fluorouracil/*therapeutic use | 2 | 10.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Comparative Study | 2 | 0.0 |
Homocysteine/*blood | 2 | 0.0 |
